H. Wu

发表

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

D. Provencher, M. Birrer, I. Vergote, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

616OPertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)

J. Tabernero, P. Hoff, J. Eng-Wong, 2017 .

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer.

P. Ascierto, A. Fasolo, J. Mataraza, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update

L. Appleman, G. Gravis, E. Yu, 2020 .

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.

D. Provencher, J. Ledermann, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib maintenance therapy in Chinese advanced-stage lung adenocarcinoma patients with EGFR mutations treated with prior chemotherapy.

Y. Wang, K. Cai, G. Xiong, 2015, Neoplasma.

Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study.

Y. Jiang, L. Shen, X. Lin, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials

M. Andjelkovic, J. Buse, R. Henry, 2015, Diabetes, obesity & metabolism.

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.

Y. Jiang, Y. Ba, R. Xu, 2019 .

KEYNOTE-365: Phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC)

E. Yu, C. Schloss, H. Wu, 2017 .

Pharmacokinetic Study of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies

S. Ramalingam, S. Strychor, S. Ramalingam, 2009, Clinical pharmacology and therapeutics.

14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC)

S. Ou, P. Janne, K. Li, 2023, Journal of Thoracic Oncology.

KEYNOTE-151: A phase Ib study of second-line pembrolizumab (Pembro) for Chinese patients (pts) with advanced or metastatic melanoma.

H. Pan, Y. Zhou, Y. Shu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.